Display options
Cite
Krysanov I, Tyapkina M. Economic Evaluetion of Fulvestrant 500 MG (F500) Versus Original Nonsteroidal Aromatase Inhibitors in Patient with Advanced Breast Canser in Russia (2 LINE THERAPY). Value Health. 2014;17(7):A637doi: 10.1016/j.jval.2014.08.2291.
Krysanov, I., & Tyapkina, M. (2014). Economic Evaluetion of Fulvestrant 500 MG (F500) Versus Original Nonsteroidal Aromatase Inhibitors in Patient with Advanced Breast Canser in Russia (2 LINE THERAPY). Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A637. https://doi.org/10.1016/j.jval.2014.08.2291
Krysanov, I, and Tyapkina, M. "Economic Evaluetion of Fulvestrant 500 MG (F500) Versus Original Nonsteroidal Aromatase Inhibitors in Patient with Advanced Breast Canser in Russia (2 LINE THERAPY)." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A637. doi: https://doi.org/10.1016/j.jval.2014.08.2291
Krysanov I, Tyapkina M. Economic Evaluetion of Fulvestrant 500 MG (F500) Versus Original Nonsteroidal Aromatase Inhibitors in Patient with Advanced Breast Canser in Russia (2 LINE THERAPY). Value Health. 2014 Nov;17(7):A637. doi: 10.1016/j.jval.2014.08.2291. Epub 2014 Oct 26. PMID: 27202276.
Copy Download .nbib Format: NLM
Share it on

Value Health. 2014 Nov;17(7):A637. doi: 10.1016/j.jval.2014.08.2291. Epub 2014 Oct 26.

Economic Evaluetion of Fulvestrant 500 MG (F500) Versus Original Nonsteroidal Aromatase Inhibitors in Patient with Advanced Breast Canser in Russia (2 LINE THERAPY).

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

I Krysanov, M Tyapkina

Affiliations

  1. Postgraduate Medical Institute, Moscow National University of Food Production, Moscow, Russia.
  2. 1st Moscow State Medical University named after I. M. Sechenov, Moscow, Russia.

PMID: 27202276 DOI: 10.1016/j.jval.2014.08.2291

[No abstract available.]

Publication Types